London · Delayed Price · Currency is GBP · Price in GBX Convatec Group Earnings Call Transcripts
Fiscal Year 2026
-
Broad-based growth across all categories supports unchanged 2026 guidance, with new product launches and capacity expansions expected to accelerate growth from 2027. Margin and EPS targets remain on track, despite inflation and regulatory uncertainties.
-
The Accelerate strategy builds on a successful turnaround, targeting 6%-8% organic revenue growth, mid-20s operating margin, and double-digit EPS growth. Growth is driven by robust innovation, new product launches across all categories, capacity expansion, and disciplined capital allocation.
Fiscal Year 2025
-
Delivered strong organic revenue and margin growth in 2025, with double-digit EPS and robust cash flow. 2026 guidance targets 5%-7% organic growth and at least 23% margin, despite reimbursement headwinds. From 2027, expects 6%-8% annual growth and mid-twenties margin.
-
Broad-based organic revenue growth and strong product launches underpin confidence in meeting 2025 and medium-term targets. Despite regulatory headwinds for InnovaMatrix, margin expansion and double-digit EPS growth are expected, supported by innovation and increased CapEx.
-
Strong H1 2025 results with 6.8% organic revenue growth, 130 bps margin expansion, and 19% EPS growth. Guidance reaffirmed despite potential 1%-2% revenue headwinds from CMS proposals, with continued investment in innovation and manufacturing capacity.
-
Organic revenue growth reached 6.7% (excluding InnovaMatrix), with broad-based gains across all categories and strong innovation driving new product launches. Guidance for 2025 is tightened, with revenue growth expected between 5.5%-7% and at least $75 million in InnovaMatrix sales.
Fiscal Year 2024
-
Achieved record 2024 results with 7.7% organic revenue growth, margin expansion, and double-digit EPS and free cash flow growth. 2025 guidance targets 5%-7% organic growth (ex-InnovaMatrix), further margin gains, and continued strong cash generation despite regulatory headwinds.
-
Organic sales growth reached 7.7% year-to-date, prompting upgraded 2024 sales and margin guidance. All business segments contributed, with strong product innovation and robust emerging market growth. Margin expansion is supported by operational improvements and lower inflation.
-
Strong H1 2024 results with 6.6% organic revenue growth, margin expansion, and robust cash flow. Guidance for 2024 and medium term reaffirmed, with new product launches and operational efficiencies supporting double-digit EPS and cash flow growth.